metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive
versus docetaxel
	atezolizumab alone
	OAK (PDL1 TC 1/2/3), 2016 Lancet 2017;389:255-265 Clin Lung Cancer 2018; 19:e405-e415 Clin Lung Cancer 2018; 19:441-449.e4 Eur. J. Cancer 2019; 107:124-132 J Thorac Oncol 2018; 13:1156-1170 J Med Econ 2019; 22:625-637 Lung Cancer 2019 Feb;128:105-112. NCT02008227	RCT	mNSCLC - L2 - PDL1 positive	atelozumab	docetaxel	patients with locally advanced or metastatic (IIIB and IV) non-small cell lung cancer (NSCLC) who have failed platinum therapy, only patients with PDL1 TC 1/2/3	347 / 337	some concern	conclusif	demonstrated 23 % decrease in deaths (OS) (PE) statistically significant 8.6-fold increase in DOR
	avelumab alone
	JAVELIN Lung 200 (PDL1 >1%), 2018 Lancet Oncol. 2018; 19:1468-1479 J Thorac Oncol 2021 Apr 9;S1556-0864(21)01832-3. NCT02395172	RCT	mNSCLC - L2 - PDL1 positive	avelumab	docetaxel	patients with stage IIIB, IV, or recurrent NSCLC with disease progression after previous platinum doublet treatment PDL1 positive population	264 / 265	some concern	suggested	inconclusive 10 % decrease in deaths (OS),deaths (OS) (PE)
	pembrolizumab (10mg/kg)
	KEYNOTE-010 (P:10 mg/kg), 2016 Lancet 2016;387:1540-50 Ann. Oncol. 2019; 30:281-289 J Thorac Oncol 2019 May;14(5):793-801. NCT01905657	RCT	mNSCLC - L2 - PDL1 positive	pembrolizumab 10 mg/kg	docetaxel	patients with previously treated (one line or more) non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells	346 / 343	high	conclusif	demonstrated 39 % decrease in deaths (OS) (PE) suggested 21 % decrease in progression or deaths (PFS) (PE)
	KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 Lancet 2016;387:1540-50 Ann. Oncol. 2019; 30:281-289 J Thorac Oncol 2019 May;14(5):793-801. NCT01905657	RCT	mNSCLC - L2 - PDL1 positive	pembrolizumab 10 mg/kg	docetaxel	patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 50% of tumour cells	151 / 152	high	conclusif	demonstrated 50 % decrease in deaths (OS) (PE) demonstrated 41 % decrease in progression or deaths (PFS) (PE) suggested 45 % decrease in deaths (OS) (extension) suggested 43 % decrease in PFS (extension)
	pembrolizumab (2mg/kg)
	KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 Lancet 2016;387:1540-50 Ann. Oncol. 2019; 30:281-289 J Thorac Oncol 2019 May;14(5):793-801. NCT01905657	RCT	mNSCLC - L2 - PDL1 positive	pembrolizumab 2 mg/kg	docetaxel	patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 50% of tumour cells	139 / 152	high	conclusif	demonstrated 46 % decrease in deaths (OS) (PE) demonstrated 41 % decrease in progression or deaths (PFS) (PE)
	KEYNOTE-010 (P: 2mg/kg), 2016 Lancet 2016;387:1540-50 Ann. Oncol. 2019; 30:281-289 J Thorac Oncol 2019 May;14(5):793-801. NCT01905657	RCT	mNSCLC - L2 - PDL1 positive	pembrolizumab 2 mg/kg	docetaxel	patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells	344 / 343	high	conclusif	demonstrated 29 % decrease in deaths (OS) (PE) inconclusive 12 % decrease in progression or deaths (PFS) (PE)
versus Standard of Care (SoC)
	durvalumab alone
	ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 Clin Lung Cancer 2016; 17:232-236.e1 Ann Oncol 2020 May;31(5):609-618. NCT02352948	RCT	mNSCLC - L2 - PDL1 positive	durvalumab	standard of care : erlotinib, gemcitabine or vinorelbine	patients with PD-L1 positive locally advanced or metastatic non small cell lung cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for stage IIIB/IV locally advanced or mNSCLC;	62 / 64	some concern	suggested	suggested 37 % decrease in deaths (OS)